An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
Phase of Trial: Phase I/II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PLATFORM
- Sponsors Celgene Corporation
- 01 Nov 2017 Status changed from not yet recruiting to recruiting, according to A Juno Therapeutics media release
- 01 Nov 2017 According to A Juno Therapeutics media release, BLA filing expected to be completed in the second half of 2018 and with approval as early as 2018.
- 13 Oct 2017 Status changed from planning to not yet recruiting.